FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.ebm
Resource TypeEvidence
IdEvidence-367928.json
FHIR VersionR6

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: Evidence 367928

version: 26; Last updated: 2025-08-18 13:22:42+0000; Language: en

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367928

identifier: FEvIR Object Identifier/367928, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-0--OG001

name: NCT03640312_otherOutcomeMeasure_0_OG001

title: Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312

citeAs:

Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Candesartan

note: ,

Outcome Measure Population Description: All randomized participants

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks - (NCT03640312)

statistic

statisticType: Count of Participants

quantity: 0 Participants

SampleSizes

-KnownDataCount
*30

AttributeEstimates

-TypeQuantity
*Percentage0 %

Source1

{
  "resourceType": "Evidence",
  "id": "367928",
  "meta": {
    "versionId": "26",
    "lastUpdated": "2025-08-18T13:22:42.074Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
    ]
  },
  "language": "en",
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Evidence/367928",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "367928",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "NCT03640312-otherOutcomeMeasure-0--OG001",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "NCT03640312_otherOutcomeMeasure_0_OG001",
  "title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312",
  "citeAs": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition": [
    {
      "description": "Candesartan",
      "note": [
        {
          "text": "Outcome Measure Population Description: All randomized participants"
        },
        {
          "text": "Outcome Measure Denominator Units: Participants"
        }
      ],
      "variableRole": "population",
      "observed": {
        "identifier": {
          "type": {
            "text": "ClinicalTrials.gov Outcome Measurement Group Id"
          },
          "value": "OG001"
        },
        "display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
      }
    },
    {
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/367896",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03640312-otherOutcome-0",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks -  (NCT03640312)"
      }
    }
  ],
  "statistic": [
    {
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000047",
            "display": "count"
          }
        ],
        "text": "Count of Participants"
      },
      "quantity": {
        "value": 0,
        "unit": "Participants"
      },
      "sampleSize": {
        "knownDataCount": 30
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0,
            "unit": "%"
          }
        }
      ]
    }
  ]
}